Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non–small-cell lung cancer harboring …
Y Zenke, K Yoh, S Matsumoto, S Umemura, S Niho… - Clinical Lung Cancer, 2016 - Elsevier
Background Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and
histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of …
histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of …
[PDF][PDF] Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients.
MN Sedano, JMC Teller, CG Muñoz, DF Redondo… - chemotherapy, 2018 - jbuon.com
Purpose: Erlotinib and gefitinib are both tyrosine kinase inhibitors (TKIs) approved for the
treatment of non-small cell lung cancer (NSCLC). Although it is well known that the increase …
treatment of non-small cell lung cancer (NSCLC). Although it is well known that the increase …
[HTML][HTML] EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction
Background Erlotinib and gefitinib are weak base drugs whose absorption and clinical
efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton …
efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton …
Gastric acid suppression is associated with decreased erlotinib efficacy in non–small-cell lung cancer
MP Chu, S Ghosh, CR Chambers, N Basappa… - Clinical lung cancer, 2015 - Elsevier
Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib
Objectives As the bioavailability of erlotinib is dependent on gastric pH, an increase in
gastric pH via the concurrent use of gastric acid suppressive medications (AS) may reduce …
gastric pH via the concurrent use of gastric acid suppressive medications (AS) may reduce …
Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non–Small Cell Lung Cancer
M Ohgami, T Kaburagi, A Kurosawa… - Therapeutic drug …, 2018 - journals.lww.com
Background: Erlotinib is used for treating non–small cell lung cancer (NSCLC). Intestinal
absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of …
absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of …
[HTML][HTML] Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib
CH Lee, MC Shen, MJ Tsai, JS Chang, YB Huang… - Scientific Reports, 2022 - nature.com
Gefitinib and erlotinib are the first-line tyrosine kinase inhibitors (TKI) for advanced non-
small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors …
small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors …
[HTML][HTML] Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR …
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers.
8017 Background: Pts with EGFR-mutant lung cancers treated with EGFR tyrosine kinase
inhibitors (TKI) develop clinical resistance, most frequently due to acquisition of EGFR …
inhibitors (TKI) develop clinical resistance, most frequently due to acquisition of EGFR …
Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation–positive non–small cell lung cancer: A multicenter phase 2 trial
S Miyamoto, K Azuma, H Ishii, A Bessho… - JAMA …, 2020 - jamanetwork.com
Importance Although the efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors forEGFRgene mutation–positive non–small cell lung cancer is well established …
inhibitors forEGFRgene mutation–positive non–small cell lung cancer is well established …
相关搜索
- erlotinib and gefitinib in patients
- egfr mutations erlotinib and gefitinib
- lung cancer erlotinib and gefitinib
- egfr mutations lung cancer
- clinical impact erlotinib and gefitinib
- egfr mutations clinical impact
- clinical impact lung cancer
- medication use efficacy of erlotinib
- clinical impact gastric acid
- multicenter phase egfr mutation
- lung cancer acid suppression
- lung cancer retrospective analysis
- pulse dose lung cancers
- lung cancer adverse events
- egfr mutations gefitinib in patients
- lung cancer gefitinib in patients